Culprit plaque morphology determines inflammatory risk and clinical outcomes in acute coronary syndrome.
Teresa GerhardtClaudio SeppeltYoussef S AbdelwahedDenitsa MetevaChristopher WolframPhilip StapmannsAslihan ErbayLukas ZandersGregor NellesJohanna MusfeldLara SieronskiBarbara E StähliRocco Antonio MontoneRocco VergalloArash HaghikiaCarsten SkurkFabian KnebelHenryk DregerTobias Daniel TrippelHimanshu RaiMichael JonerJens KlotschePeter LibbyFilippo CreaNicolle KränkelUlf LandmesserDavid Manuel Leistnernull nullPublished in: European heart journal (2023)
This study demonstrates a distinct inflammatory response and a lower risk of MACE+ following IFC-ACS. These findings advance our understanding of inflammatory cascades associated with different mechanisms of plaque disruption and provide hypothesis generating data for personalized anti-inflammatory therapeutic allocation to ACS patients, a strategy that merits evaluation in future clinical trials.
Keyphrases
- acute coronary syndrome
- inflammatory response
- clinical trial
- end stage renal disease
- percutaneous coronary intervention
- antiplatelet therapy
- coronary artery disease
- anti inflammatory
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- prognostic factors
- electronic health record
- lipopolysaccharide induced
- toll like receptor
- open label
- current status
- phase iii